Construction and validation of cell cycle-related prognostic genetic model for glioblastoma

Runpeng Zhou,Kai Zhang,Tingting Dai,Zeshang Guo,Tian Li,Xinyu Hong

DOI: https://doi.org/10.1097/md.0000000000039205

IF: 1.6

2024-10-09

Medicine

Abstract:Gliomas account for up to 30% to 40% of all brain tumors and 80% of all malignant brain tumors. Among them, glioblastoma is the most common and aggressive primary malignant brain tumor in adults, accounting for more than half of all malignant gliomas. Glioblastomas are characterized by high recurrence and mortality rates, and a low cure rate. [ 1 ] The 5-year survival rate of patients with malignant glioma is < 30% for grade III (anaplastic astrocytoma) and 5% for grade IV (glioblastoma) tumors. [ 2–4 ] Age, tumor grade, clinical treatment strategies, and the molecular phenotype of the tumor markedly affect the prognoses of patients with gliomas. The treatment efficacy for gliomas is suboptimal, and the prognosis of these patients is highly variable. [ 5 , 6 ] The standard treatment for glioblastoma typically includes gross total resection surgery, focal radiotherapy targeting the tumor area, temozolomide chemotherapy, and a certain dose of radiotherapy as the standard treatment. [ 7 , 8 ] Although these treatment modalities can extend patients' survival to some extent, all glioblastomas eventually progress or recur. [ 7 ] Existing prognostic models often rely on clinical pathological features, but they have certain limitations, such as low predictive accuracy and lack of personalized prediction. [ 9 ] Therefore, establishing an individualized prognostic scoring system based on important prognostic factors may facilitate the provision of individualized risk assessment and clinical treatment.

medicine, general & internal